Receptive to Receptos Barron's Faheem Hasnain, chief executive, previously developed daclizumab for RMS as CEO of Facet, which was acquired by Abbott Laboratories (ABT) in April 2010. Not only does he have a great track record developing multiple sclerosis (MS) drug candidates, but ... |
